OPTN News and Press, OptiNose Inc. From 08/11/21

The following slide deck was published by OptiNose, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: OptiNose, Inc. 2021 Q2 - Results - Earnings Call Presentation

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa....

Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis Sufferers in the U.S. YARDLEY, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Optinose...

Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and Webcast to be held August 11, 2021 at 8:00 a.m. Eastern Time YARDLEY, ...

OptiNose's Xhance is already approved in one indication with another set to read out pivotal data from two trials in late 2021 and early 2022. Xhance had $48.4 million in sales in the sinusitis patients with nasal polyps in 2020 and looks to grow that to at least $80 million in 2021. ...

YARDLEY, Pa., June 24, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced Dr. Per Djupesland received the European Inventor Award 2021 in the Industry category from ...

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care - Evidenced-based expert algorithm separates EDS-FLU, marketed as XHANCE®, from standard intranasal steroid sprays, recommending it for p...

YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upda...

OptiNose (OPTN) has added ~13.0% in the post-market after the company disclosed a purchase of~34K common stock by the company’s chief commercial officer, Victor M Clavelli.With the purchase of shares at $3.06 apiece Clavelli has raised its stake in the company to ~1...

The following slide deck was published by OptiNose, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: OptiNose, Inc. 2021 Q1 - Results - Earnings Call Presentation